Varun Reddy, MD
Neurology · Johnson City, NYNPI 1710214259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,450 of the $37,161 with a category attached, or 65.8%. Johnson & Johnson accounts for 69.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $31,186 and has fallen 96.6% since, to $1,045 in 2025.
Across 130 payments — averaging $285.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$26K
- Chiesi USA, Inc.$3K
- Penumbra, Inc.$3K
- Silk Road Medical, Inc.$1K
- Imperative Care, Inc$1K
- Stryker$823
- plus $2K from 17 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$24,45066%
- Travel & lodging$6,23017%
- Food & beverage$6,18117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 26 | $25,764 |
| Chiesi USA, Inc. | 4 | $3,226 |
| Penumbra, Inc. | 20 | $2,630 |
| Silk Road Medical, Inc. | 8 | $1,265 |
| Imperative Care, Inc | 12 | $1,234 |
| Stryker | 25 | $823 |
| Medtronic(3 entities) | 11 | $487 |
| Balt USA, LLC | 3 | $358 |
| AbbVie | 2 | $242 |
| UCB, Inc. | 4 | $181 |
| Haemonetics Corporation | 3 | $155 |
| Microtransponder, Inc. | 1 | $127 |
| Biogen | 1 | $125 |
| SK Life Science, Inc. | 1 | $125 |
| Portola Pharmaceuticals, LLC | 1 | $88 |
| AstraZeneca | 1 | $79 |
| Amgen | 1 | $78 |
| Integra Lifesciences Corporation | 1 | $55 |
| Medicure Pharma Inc. | 1 | $52 |
| Boston Scientific | 1 | $21 |
| Terumo Medical Corporation | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$25,337
- CLEVIPREX$3,226
- Penumbra System$2,137
- ENROUTE Transcarotid Neuroprotection System$1,137
- ENROUTE Transcarotid Stent System$1,137
- ENHANCE Transcarotid Peripheral Access Kit$1,137
- ENROUTE 0.014 Guidewire$1,137
- ZOOM 88-T LARGE DISTAL PLATFORM$628
- ZOOM REPERFUSION CATHETER$359
- Optima Coil System$194
- 3D Revascularization$138
- TREVO$128
- DURYSTA$125
- XCOPRI$125
- Carrier Delivery Catheter$120
- TracStarLargeDistalPlatform$119
- Zoom88LargeDistalPlatform$119
- Zoom88_TLargeDitalPlatform$119
- ZoomReperfusionCatheter$119
- TEFLARO$117
How this compares
$37,161 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 16 | $8,514 |
| ClopidogrelClopidogrel Bisulfate | 36 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $79 | $8,51416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.
Other neurology in Johnson City
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.